Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT03568162

Public ClinicalTrials.gov record NCT03568162. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 3:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of ISB 830 in Adult Subjects With Moderate to Severe Atopic Dermatitis.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of ISB 830 in adults with moderate to severe atopic dermatitis. The study will be conducted in 2 Parts, with dosing Groups 1-4 comprising Part 1, and dosing Groups 5-6 comprising Part 2. All subjects will receive open-label ISB 830 after a 16 week blinded treatment period.

Study identification

NCT ID
NCT03568162
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Ichnos Sciences SA
Industry
Enrollment
462 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 30, 2018
Primary completion
Aug 10, 2020
Completion
Aug 2, 2021
Last update posted
Aug 22, 2022

2018 – 2021

United States locations

U.S. sites
34
U.S. states
18
U.S. cities
32
Facility City State ZIP Site status
Ichnos Investigational Site 129 Birmingham Alabama 35209
Ichnos Investigational Site 120 Clovis California 93711
Ichnos Investigational Site 105 Rolling Hills Estates California 90274
Ichnos Investigational Site 106 Bridgeport Connecticut 06606
Ichnos Investigational Site 146 Danbury Connecticut 06810
Ichnos Investigational Site 142 Brandon Florida 33511
Ichnos Investigational Site 143 Fort Myers Florida 33912
Ichnos Investigational Site 148 Lake City Florida 32055
Ichnos Investigational Site 141 Lake Worth Florida 33461
Ichnos Investigational Site 140 Miami Florida 33156
Ichnos Investigational Site 123 Miami Florida 33175
Ichnos Investigational Site 147 Ormond Beach Florida 32174
Ichnos Investigational site 101 Tampa Florida 33607
Ichnos Investigational Site 135 Tampa Florida 33612
Ichnos Investigational Site 115 Newnan Georgia 30263
Ichnos Investigational Site 139 Savannah Georgia 31406
Ichnos Investigational Site 112 Plainfield Indiana 46168
Ichnos Investigational Site 125 West Des Moines Iowa 50265
Ichnos Investigational Site109 New Orleans Louisiana 70115
Ichnos Investigational Site 126 St Louis Missouri 63141
Ichnos Investigational Site 144 Las Vegas Nevada 89120
Ichnos Investigational Site 117 Verona New Jersey 07044-2946
Glenmark Investigational Site 102 Forest Hills New York 11375
Ichnos Investigational Site 114 Medford Oregon 97504-9741
Ichnos Investigational Site 133 Hazleton Pennsylvania 18201
Ichnos Investigational Site 122 Philadelphia Pennsylvania 19103
Ichnos Investigational Site 132 Chattanooga Tennessee 37421
Ichnos Investigational Site 119 Houston Texas 77004
Ichnos Investigational Site 138 Pflugerville Texas 78660
Ichnos Investigational Site 116 San Antonio Texas 78258
Ichnos Investigational Site 110 Waco Texas 76710
Ichnos Investigational Site 103 Newport News Virginia 23606-4537
Ichnos Investigational Site 131 Richmond Virginia 23220
Ichnos Investigational Site 136 Spokane Washington 99224

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03568162, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 22, 2022 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03568162 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →